Discovery of potent bifunctional small molecules targeting DNA-PK and HDAC6 with desirable pharmacokinetic properties for acute myeloid leukemia treatment | Synapse
March 3, 2026
Discovery of potent bifunctional small molecules targeting DNA-PK and HDAC6 with desirable pharmacokinetic properties for acute myeloid leukemia treatment
Key Points
Treatment improved acute myeloid leukemia response rates with specific targeting of dna-pk and hdac6.
The small molecules demonstrated desirable pharmacokinetic properties enhancing their therapeutic potential.
Observational analysis assessed the efficacy of these bifunctional agents against cancer cell lines in vitro.
This innovation may enable better treatment options for acute myeloid leukemia, illuminating novel therapeutic strategies.